Physician profile
Romsel Ang
NPI 1467537688
$2,232.95
in general payments reported to CMS, 2019-2025
19 companies · $647 in 2025
The $647 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.81 · 2020: $153 · 2021: $30.19 · 2022: $331 · 2023: $459 · 2024: $562 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,667.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $419.73 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $366.06 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $260.15 | 2022-2025 | Ubrelvy, Vraylar |
| Daiichi Sankyo INC. | $245.94 | 2023-2025 | Injectafer |
| Silk Road Medical, INC. | $167.86 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Pfizer INC. | $126.16 | 2019-2025 | |
| Glaxosmithkline, LLC. | $101.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $97.32 | 2023-2024 | |
| Lilly USA, LLC | $95.49 | 2020-2024 | Mounjaro, Zepbound |
| Allergan, INC. | $59.81 | 2020 | |
| Amgen INC. | $59.77 | 2020-2025 | Repatha, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.52 | 2024-2025 | Jardiance |
| Shield Therapeutics INC | $40.91 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $33.60 | 2020 | |
| Merck Sharp & Dohme LLC | $28.43 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $23.88 | 2023 | |
| Janssen Pharmaceuticals, INC | $20.45 | 2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $18.58 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romsel Ang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.